Dermatomyositis Market : Information, Figures and Analytical Insights 2020

By: X herald

Dermatomyositis – Pipeline Insight, 2020

The Dermatomyositis Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the impact of COVID-19 (Corona Virus) on the product industry chain based on the upstream and downstream markets, on various regions and major countries and on the future development of the industry are pointed out.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/04282010514/dermatomyositis-pipeline-insight-2020/inquiry?source=xherald&Mode=12

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Dermatomyositis Market: Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Inc., CSL Behring, Pfizer, Kezar Life Sciences, Inc., Beijing Continent Pharmaceutical Co, Ltd. and others.

August 05, 2020: Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). The Company expects to report topline results from this study in the fourth quarter of 2021.

“We are grateful to the participants for their commitment and to all of our investigators and their staff for their support of the study and dedication to completing enrollment on time, despite COVID-19,” said Barbara White, M.D., Chief Medical Officer of Corbus. “Enrollment exceeded our expectations, which we think speaks to the unmet need of dermatomyositis patients for new treatment options, especially options without some of the toxicities associated with chronic immunosuppression.”

The Company’s Phase 3 DETERMINE study has enrolled 176 subjects in the largest, randomized, double-blind, placebo-controlled DM study to date. This study is being conducted in North America, Europe, and Asia. Patients in the study are randomized 2:1:2 to either receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day or placebo twice per day for 52 weeks with a follow-up period of 4 weeks.

June 12, 2018: Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis

EXTON, Pa., June 12, 2018— Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, today announced topline results from the Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis.

The objective of the multi-center, global, Phase 2, randomized, double blind, placebo-controlled trial was to assess the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), disease-specific autoantibodies and immunogenicity of IMO-8400 in adult patients with dermatomyositis.  The primary objective of the trial was to assess the change from baseline in the Cutaneous Dermatomyositis Disease Area and Severity Index (“CDASI”) activity score, an outcome measure of skin disease severity, versus placebo.

30 eligible subjects were randomized to 1 of 3 treatment groups to receive once weekly subcutaneous injections of 0.6 or 1.8 mg/kg of IMO-8400 or placebo for up to 24 weeks. The mean CDASI activity score was in the severe range in all three cohorts despite background treatment with immunosuppressive drugs and/or systemic corticosteroid drugs in 17 of the 30 subjects.

The trial did not meet its primary endpoint of statistically significant change from baseline in the CDASI activity score versus placebo.

The research study evaluates the overall size of the market, by making use of a bottom-up approach, wherein data for different industry verticals, and end-user industries and its applications across various product types have been recorded and predicted during the forecast period. These segments and sub-segments have been documented from the industry specialists and professionals, as well as company representatives, and are outwardly validated by analyzing previous years’ data of these segments and sub-segments for getting an accurate and complete market size.

Influence Of The Dermatomyositis Market Report:

-Comprehensive assessment of all opportunities and risk in the Dermatomyositis market.

– Dermatomyositis market recent innovations and major events.

-Detailed study of business strategies for growth of the Dermatomyositis market-leading players.

-Conclusive study about the growth plot of Dermatomyositis market for forthcoming years.

-In-depth understanding of Dermatomyositis market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Dermatomyositis market.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/04282010514/dermatomyositis-pipeline-insight-2020?source=xherald&Mode=12

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Analytical Tools: The Global Dermatomyositis Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please connect with our sales team (sales@marketinsightsreports.com).

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on mediarelations@xherald.com.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.